truncation and the production of a 35 kDa A chain. Analysis of purified fibrinogen revealed expression of the abnormal A chain in 4 family members, but found no normal fibrinogen in the 2 hypofibrinogenemic patients. This paradox was resolved when they, and their asymptomatic mother, were found to be heterozygous for a second A mutation, a GT TT splice site mutation in intron 4 (IVS4+1 G>T). However, compound heterozygosity for both mutations was required for the expression of severe hypodysfibrinogenemia and clinical symptoms.
Introduction
Fibrinogen is an approximately 340 kDa disulfide-bonded dimer of 3 different protein chains.
The A , B , and chains are encoded by 3 separate genes within a 50-kb region of chromosome 4q28-q31 (reviewed in Nieuwenhuizen et al. 1 ). The glycoprotein is synthesized in hepatocytes and secreted to yield a normal steady-state plasma concentration of 1.5 to 3.5 mg/mL with a halflife of about 4 days. 2 As the precursor of the clot forming protein fibrin and as a mediator of platelet aggregation, fibrinogen is a key component of the hemostatic system. 1 As evidenced by the high rate of spontaneous abortions in hypofibrinogenemic women, 3 it is also important for the successful conclusion of pregnancy.
Fibrinogen abnormalities can be classified according to whether there is low or no circulating levels of normal protein (hypo-or afibrinogenemia), a mutated species (dysfibrinogenemia) or a combination (hypodysfibrinogenemia). Reports 1, 4 on approximately 350
families with dysfibrinogenemia reveal that about half of the cases are clinically silent, a quarter of them have a tendency towards bleeding and another quarter show predisposition for thrombosis with or without bleeding. Mutations have been found on all the fibrinogen chain genes, but those of the A chain have been most prevalent, 5, 6 particularly a mutation of the invariant 5' splice site of intron 4 from GT to TT (IVS4+1 G>T), which results in afibrinogenemia in the homozygous state. 7 Several nonsense mutations leading to a truncated fibrinogen A -chain have been reported. [7] [8] [9] [10] [11] [12] [13] [14] Clinical complications can vary widely, from asymptomatic to afibrinogenemic, depending on whether the patient is heterozygous or homozygous, as well as both the extent of the truncation and any confounding mutations.
In this study we describe a novel fibrinogen mutation -designated Fibrinogen Keokukthat truncates the A -chain at Gln328 of the mature protein. Four family members were shown to
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These individuals were found to be compound heterozygotes for the truncation as well as the IVS4+1 G>T mutation, resulting in hypodysfibrinogenemia.
Patients and methods

Patients
Three generations of a non-consanguineous American family of European descent were studied: the mother (referred to as I.2), her 3 children (II.1, II.2, II.3), and 2 grandchildren (III.1 and III. 2) from her third child. II.1 and II.2 have no offspring, though II.1 had 6 miscarriages. II.1's husband, and II.3's wife, the mother of III.1 and III.2, were not studied. The father (I.1), deceased of lung cancer, was not known to have any hemostatic disorders. Only II.1 and II.2 had hypofibrinogenemia and problems with bleeding and thrombosis. Informed consent was obtained from all participants.
Sample collection and preparation
Blood for analysis of hemostasis was collected into tubes containing 1/10 volume of 0.105 M trisodium citrate anticoagulant (Becton Dickinson, Franklin Lakes, NJ). Platelet-rich plasma was obtained by centrifugation (100g x 10 minutes, room temperature (RT)). The remaining blood was centrifuged (1000g x 10 minutes, 4 o C) to obtain platelet-poor plasma (PPP), aliquoted, and stored at -80 o C. Blood for DNA analysis was collected into tubes containing 1/90 volume 15% K 3 EDTA. Unfractionated samples were transported at RT for up to 3 days prior to analysis.
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Hemostasis functional analysis
Total fibrinogen concentration was measured using the Laurell immunoelectrophoresis method. 16 As the Laurell method had a sensitivity level of only 0.45 mg/mL, fibrinogen levels for II.2, II.3, and III.2 were also measured by fibrinopeptide A release as previously described. 17 Platelet count was performed with a Thrombocounter C (Beckman Coulter, Brea, CA).
Platelet aggregation was studied using a PAP-4 (Bio-Data Corp., Horsham, PA) by adding 5 µL of 2 µM calcium ionophore U-46619 (Sigma, St. Louis, MO) to 250 µL of platelet-rich plasma and stirring (1000 rpm, 4 minutes, 37 o C).
ELISA kits were used for measuring t-PA and PAI-1 levels (BioPool, Burlington, ON, Canada), and anticardiolipin antibodies (TheraTest Laboratories, Chicago, IL). Analysis for antifibrinogen and anti-factor XIII antibodies was carried out by ELISA as previously described, 18 using purified fibrinogen or FXIII as antigens.
Factor XIII activity was assessed by examining clot solubility in 5 M urea. 19, 20 Activated partial thromboplastin time (aPTT), prothrombin time (PT), mixing tests, and assays for factors VIII, IX, and XI, and clottable fibrinogen (using a modified Clauss method 21, 22 ) were performed using an MLA Electra 800 instrument and antithrombin levels were measured using an MLA Electra 900 instrument (both from Medical Laboratory Automation, Inc., Pleasantville, NY).
Thrombin time (TT) and plasminogen activity were determined with the respective STA kits, 
Fibrinogen purification
Three mL of PPP was dialyzed against 10 mM sodium phosphate, pH 6.5, 1 mM EDTA and subjected to anion exchange chromatography on a DEAE-Sepharose column equilibrated with the same buffer. After loading, the column was washed with 10 mM sodium phosphate, pH 6.0, 1 mM EDTA until the absorbance at 280 nm returned to baseline. Remaining plasma proteins, including fibrinogen, were eluted with 10 mM sodium phosphate, pH 6.0, 1 mM EDTA, 200 mM NaCl, and fractions corresponding to these proteins were pooled. Fibrinogen was purified from this pool by precipitation with 35% saturated ammonium sulfate. After washing the pellet twice with 40% saturated ammonium sulfate it was resuspended in 20 mM HEPES, pH 7.4, 150 mM NaCl and dialyzed against the same buffer. Normal fibrinogen was purified from 3 mL plasma using the same method or by precipitation with 22% saturated ammonium sulfate. The pellet was washed twice with 25% saturated ammonium sulfate, resuspended in the HEPES buffer and dialyzed. 
Fibrin clot function and structure
DNA sequence analysis
Exon 5 of the fibrinogen A -chain gene was amplified by 37 cycles of PCR using the following primers: A VF corresponding to nucleotides 3715-3732, (5'CAGGAACTCAATAGACGT 3') and A VR primer (5'GACCAGTTTTTCTGTGTGGTACTC 3') corresponding to the complementary nucleotides 4577-4554. 28 The PCR product was run on a 1% agarose gel and the band with the expected size was purified with the Gel Extraction Kit (QIAGEN, Santa Clarita, CA). The purified products were sequenced using both A VF and A VR primers (GlaxoWellcome DNA sequence facility, UNC at Chapel Hill, NC).
All exons and intron-exon boundaries of the fibrinogen genes were amplified from genomic DNA using standard PCR protocols. PCR products were purified in MultiScreen 96 PCR plates (Millipore, Billerica, MA), and sequenced using the BigDye Terminator v3.1 Cycle
Sequencing Kit and a 3100-Avant capillary DNA sequencer (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Primers were designed from the published FGA (Genbank M64982), FGB (Genbank M64983) and FGG (Genbank M10014) sequences.
Results
Case Histories
For personal use only. on . by guest www.bloodjournal.org From Two Caucasian siblings, a 53-year-old female (II.1) and a 49-year-old male (II.2) (arrow in Figure 1 ) have a life-long history of prolonged bleeding following trauma. In addition, II.1 had six miscarriages. Both were previously diagnosed with hypofibrinogenemia and were reported to be negative for Factor V Leiden. Their parents (I.1 and I.2), a 44-year-old male sibling (II.3) and his 2 children (III.1 and III.2) have no history of bleeding or thrombosis. As an adult, II.1 reported having oral surgery for impacted molars with cryoprecipitate infused prior to the procedure and "a few units" infused every three days post-surgery until bleeding stopped, all without complication. At age 43, II.2 underwent total hip arthroplasty due to aseptic necrosis of the left hip. He was prepared for surgery with cryoprecipitate to raise his circulating fibrinogen to ~1.5 mg/mL.
The procedure was uneventful, and postoperatively he was given 10-15 units of cryoprecipitate daily to maintain the fibrinogen concentration between 1.0 and 1.5 mg/mL. Five days after surgery, he began experiencing weakness and malaise, and on day eight cryoprecipitate was discontinued. On day 10, after complaining of chest pain, imaging studies revealed multiple pulmonary emboli and thrombi in both femoral veins. An inferior vena cava filter was inserted, and he was treated with anticoagulants for 3 months.
Eighteen months after surgery II.2 presented with leg ischemia secondary to emboli originating from a thrombus in the thoracic descending aorta. Removal of the aortic thrombus was performed and cryoprecipitate was given post-operatively for several days. Once again, he developed pulmonary emboli and intravenous catheters became occluded by thrombi. He was treated with subcutaneous low molecular weight heparin and the thrombi slowly resolved. Three years after the original hip surgery, thrombectomy was performed to remove femoral arterial clots. No cryoprecipitate was administered, and no excessive bleeding was observed. He is currently receiving long-term anticoagulation with low molecular weight heparin and aspirin, and has had no recent thrombotic episodes. 
Hemostasis factor studies
Results of coagulation studies for the 2 hypofibrinogenemic patients (II.1 and II.2) are presented in Table 1 . The PT and TT times were greatly prolonged, but admixture of normal plasma normalized both. Factor VIII was found to be somewhat elevated in II.1 (Table 1) , and in family members I.2 and II.3 (data not shown). Plasminogen levels for both II.1 and II.2 were normal; t-PA and PAI-1 were normal in II.1, but were elevated in II.2 as might be expected in patients experiencing thrombosis. 29, 30 Both had a normal platelet count and normal platelet aggregation was obtained with the calcium ionophore U-46619. Protein C, protein S, and antithrombin levels for II.2 were normal (I.1's levels were not determined), and tests for lupus anticoagulant, antifibrinogen, anti-FXIII and anticardiolipin antibodies were negative for II.1 and II.2.
Fibrinogen and fibrin clot studies
No fibrinogen could be detected in the platelet-poor plasma of patients II.1 and II.2 by immunoelectrophoresis but, as indicated in Table 1 , low concentrations of fibrinogen were found with the modified Clauss procedure and fibrinopeptide quantitation. Fibrinogen concentrations were normal in the other family members (Figure 1 ).
Plasma clot lysis induced by t-PA was greatly retarded, and plasma clots from II.2 were resistant to compression by centrifugation, especially when compared to normal plasma clots made with the same fibrinogen levels as II.2 (Table 1 ). In addition, II. Immunoblotting experiments (shown for patient II.2 in Figure 3 ) with an antiserum specific for the A 241-476 segment of human fibrinogen confirmed that the ~35 kDa constituent was a derivative of the A chain of the normal protein. For
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The nature of the defect implied by the prolonged thrombin time (Table 1) 
DNA analysis
Because of the presumed site of the Keokuk putative mutation deduced from immunoblotting Nonsense mutations have been reported along the whole length of the fibrinogen Achain gene, and homozygosity can result in dysfibrinogenemia, 9,13 hypodysfibrinogenemia 8,11 or often afibrinogenemia 7, 12, 14, 31 depending on the extent of the truncation. As with Fibrinogen Keokuk, heterozygous family members usually had normal fibrinogen concentrations, though with diminished allelic expression 8, 11 and in other cases a significant polymerization defect. 10, 32 For instance, heterozygotes for Fibrinogen Perth 32 expression studies using purified full length A C (residues 221-610) and its N and C-terminal fragments established that the A C domain contains additional independent cryptic t-PA and plasminogen binding sites located in the region from 392-610. 40 The loss of these sites in fibrinogen Keokuk through truncation at residue 328 may contribute to the thrombotic phenotype Experimentally, afibrinogenemic mice also miscarry at the time of trophoblast infiltration (day 9-10). 41 This family study provides a unique insight as to how 2 mutations, without untoward consequences in carriers of either mutation, may produce severe manifestations in compound heterozygotes, originally diagnosed with simple hypofibrinogenemia. Regardless of the precise molecular explanations for thrombogenicity, the near fatal post-surgical thrombosis following the administration of cryoprecipitate to our patient II.2 illustrates the risk associated with aggressive replacement therapy for raising the circulating concentration of fibrinogen without adequately characterizing the nature of the hypodysfibrinogenemia. 
